SAN DIEGO, June 19, 2026
Fapon Biopharma and MOTE Therapeutics have announced plans to present their innovative dual-targeting, dual-platform B-cell immunotherapy franchise at the BIO International Convention 2026, highlighting a next-generation approach designed to achieve deep and durable B-cell depletion across autoimmune diseases and oncology indications. The companies will showcase a portfolio built around complementary therapeutic modalities, combining a trispecific T-cell engager (TCE) platform with an advanced in vivo CAR-T therapy platform, both targeting the clinically validated B-cell antigens CD19 and BCMA. The announcement underscores the growing momentum behind next-generation immunotherapies that aim to improve efficacy, durability, and accessibility while addressing limitations associated with existing cell therapy and immune-engaging technologies. Both lead programs are expected to reach important clinical milestones within the next six months, positioning the franchise as a promising contender in the rapidly evolving field of B-cell immunotherapy.
Dual-Platform Strategy Targets Autoimmune and Oncology Diseases
At the center of the companies’ presentation is a differentiated franchise designed to deliver potent and sustained B-cell depletion through two complementary therapeutic approaches. The first program, FPE024, is a potential best-in-class CD19×BCMA×CD3 trispecific T-cell engager, engineered to selectively redirect immune cells against pathogenic B cells involved in autoimmune diseases. The program is expected to enter regulatory filing activities with an Investigational New Drug (IND) submission targeted for early 2027.
The second program, MTX001, utilizes MOTE Therapeutics’ proprietary mobilize™ targeted lipid nanoparticle (tLNP) platform to deliver an in vivo CAR-T therapy targeting both CD19 and BCMA. Unlike traditional ex vivo CAR-T approaches that require complex manufacturing processes, the in vivo strategy seeks to generate therapeutic CAR-T cells directly within the patient’s body, potentially simplifying treatment delivery and expanding accessibility. An investigator-initiated first-in-human study for MTX001 is expected to begin during the fourth quarter of 2026.
Proprietary Platforms Drive Next-Generation Biologic Innovation
Advertisement
The strength of the franchise is supported by two advanced technology platforms developed by the companies. Fapon Biopharma contributes its proprietary human-cynomolgus cross-reactive VHH T-cell engager platform, which was designed to overcome key challenges associated with traditional multispecific immune cell engagers, including limited therapeutic windows and manufacturing complexity. The platform enables scalable GMP manufacturing while supporting flexible molecular design and broad therapeutic applicability.
MOTE Therapeutics contributes its breakthrough mobilize™ targeted LNP platform, a modular gene delivery system designed to achieve cell-specific targeting and extrahepatic tissue distribution without requiring chemical conjugation. Together, these technologies create a powerful engine for developing innovative biologics capable of addressing complex autoimmune diseases, hematologic malignancies, and solid tumors through precise immune system modulation.
Expanding a Pipeline of First-in-Class Immunotherapies
Beyond the dual B-cell depletion franchise, Fapon Biopharma and MOTE Therapeutics continue advancing a broader portfolio of novel biologics and immune therapies. Leading programs include FP008, a first-in-class PD1×IL10M fusion protein currently in Phase I development for immuno-oncology, and FP012, a first-in-class TL1A×IL10M fusion protein targeting inflammatory bowel disease and autoimmune disorders. Additional pipeline candidates include FPE021, a next-generation CDH17-targeting T-cell engager for gastrointestinal cancers. The companies’ growing pipeline reflects increasing investment in precision immunology, targeted biologics, and innovative cell therapy technologies capable of delivering meaningful clinical benefits.
As demand for advanced immune-modulating therapies continues to rise globally, the presentation at BIO 2026 highlights the companies’ commitment to developing transformative treatment options while pursuing strategic collaboration and licensing opportunities that can accelerate development and commercialization worldwide.
Source: Fapon Biopharma press release
